The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pathologic response and safety of neoadjuvant pembrolizumab with or without entinostat in muscle-invasive urothelial cancer (MIUC).
 
Tracy Rose
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GeneCentric (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Pooja Ghatalia
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb Foundation (Inst); Merck (Inst)
 
Allison Deal
No Relationships to Disclose
 
Marc Bjurlin
Consulting or Advisory Role - Intuitive Surgical; Telix Pharmaceuticals; UroGen pharma
 
Hung-Jui Tan
No Relationships to Disclose
 
Young Whang
Research Funding - Amgen (Inst); Arvinas (Inst); Clovis Oncology (Inst); Novartis (Inst)
 
Blaine Brower
No Relationships to Disclose
 
Mary Dunn
No Relationships to Disclose
 
William Kim
Employment - Focal Medical, Inc. (I)
Leadership - Focal Medical, Inc. (I)
Stock and Other Ownership Interests - Abbvie; Amgen; Apellis Pharmaceuticals; Arvinas; BeiGene; Bristol-Myers Squibb; ImmunityBio; Lilly; Lilly; Moderna Therapeutics; Novo Nordisk; Revolution Medicines; Tango Therapeutics
Consulting or Advisory Role - Focal Medical, Inc. (I)
Research Funding - Merck
Patents, Royalties, Other Intellectual Property - PurIST (Purity Independent Subtyping of Tumors) (I)
Other Relationship - Merck
 
Matthew Milowsky
Stock and Other Ownership Interests - Gilead Sciences; Merck; Pfizer
Research Funding - Accuray (Inst); Acrivon Therapeutics (Inst); Alliance for Clinical Trials in Oncology (Inst); Alliance Foundation Trials (Inst); ALX Oncology (Inst); Arvinas (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Flare Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Hoosier Cancer Research Network (Inst); Loxo/Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); OncoC4 (Inst); PCCTC (Inst); Roche (Inst); Seagen (Inst)
Other Relationship - Elsevier; Medscape; Prime Education; Research to Practice
(OPTIONAL) Uncompensated Relationships - G1 Therapeutics; Loxo/Lilly